check_circleStudy Completed

Hypogonadism, Paraplegia, Bone Density, Osteoporosis

Efficacy of Nebido on bone mineral density (BMD) in hypogonadal paraplegic patients with confirmed osteoporosis

Trial purpose

Both conditions hypogonadism and immobilisation (paraplegia) may contribute or lead to decreased bone mineral density resp osteoporosis. In this study bone mineral density is assessed in hypogonadal paraplegic patients, who are on standard prophylactic therapy for osteoporosis and and on a standard physiotherapy exercise program one group receiving Nebido for testosterone replacement (TRT). The additional effect of TRT on bone mineral density / osteoporosis is assessed (CT scan lumbar spine).

Key Participants Requirements

Sex

Male

Age

18 Years

Trial summary

Enrollment Goal
26
Trial Dates
September 2005 - May 2009
Phase
N/A
Could I Receive a placebo
No
Products
Nebido (Testosterone Undeconate, BAY86-5037)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, Germany

Primary Outcome

  • Bone mineral density (CT lumbar spine)
    date_rangeTime Frame:
    12 weeks after 4th injection
    enhanced_encryption
    Safety Issue:
    No

Trial design

Nebido® Therapy in Hypogonadal Male Patients with Osteoporosis Associated with Paraplegia Compared with Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients with Osteoporosis Associated with Paraplegia
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A